Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds

Study Overview
=================
Brief Summary
-----------------
To observe the effect of different antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds. And further combined with proteomic methods to explore serological markers that can be used to accurately predict the prognosis of such patients.

Detailed Description
-----------------
Cerebral microbleeds (CMBs) are caused by microvascular lesions in the brain, which is a subclinical deposition of hemosiderin after the damage of microvascular. Antithrombotic drug are widely used in the secondary prevention of patients with ischemic stroke. Studies have shown that antithrombotic drug can increase the incidence of intracranial hemorrhage in ischemic stroke patients with cerebral microbleeds. For such patients, how to carry out effective and safe antithrombotic therapy is still unclear. We will study from two aspects: 1) We designed a cohort registration study to observe the prognosis and progress of CMBs in ischemic stroke patients one year after using various antithrombotic drugs. 2) Data independent acquisition quantitative proteomics (DIA quantitative proteomics) will be used to screen serum protein markers that may affect the prognosis of ischemic stroke patients with CMBs.

Official Title
-----------------
Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds

Conditions
-----------------
Ischemic Stroke

Intervention / Treatment
-----------------
* Drug: Antithrombotic drugs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed clinically as ischemic stroke; Age ≥ 40 years; Onset time ≤ 3 months; Informed consent was signed. Exclusion Criteria: Patients with symptomatic intracranial hemorrhage; bleeding lesion > 10 mm was found on SWI; Vascular malformations, tumors, abscesses or other major non ischemic brain diseases were present; There are contraindications for antithrombotic drugs use; Serious systemic diseases; Refusal to sign informed consent or poor compliance.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Antithrombotic drugs|The purpose of our study is to observe the effect of various antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase of cerebral microbleeds | How many cerebral microbleeds increased after 1 year of antithrombotic drugs treatment. The number of microbleeds will be detected by MR-SWI. | 1 year after onset | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stroke recurrence rate | recurrence rate of ischemic stroke | 1 year after onset | 
| The incidence of cerebral hemorrhage |  | 1 year after onset | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ischemic Stroke, microbleeds, Proteomics, antithrombotic drug